La chaîne d'options affiche les données clés des options sur actions de Perspective Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Perspective Therapeutics..

Perspective Therapeutics (AMEX:CATX) Stock, Chaîne d'Options

PERSPECTIVE THERAPEUTICS INC

Perspective Therapeutics

Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics Inc

UBS analyst Gavin Parsons maintains Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) with a Buy and raises the price target from $255 to $280.

News

Price Target

Analyst Ratings

UBS Maintains Buy on Boeing, Raises Price Target to $280

RBC Capital analyst Conor McNamara maintains Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Outperform and raises the price target from $193 to $204.

RGEN

RBC Capital Maintains Outperform on Repligen, Raises Price Target to $204

UBS analyst John Lovallo maintains Armstrong World Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AWI#NYSE">AWI</a>) with a Neutral and raises the price target from $158 to $178.

UBS Maintains Neutral on Armstrong World Indus, Raises Price Target to $178

Baird analyst Shrenik Kothari maintains Varonis Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNS#NASDAQ">VRNS</a>) with a Outperform and raises the price target from $58 to $63.

VRNS

Baird Maintains Outperform on Varonis Systems, Raises Price Target to $63

WIIM

ALAB

Astera Labs shares are trading higher after Morgan Stanley maintained an Overweight rating and raised its price target from $99 to $125.

IDEX shares are trading lower after the company lowered FY25 EPS guidance below estimates.

UBS analyst William Appicelli maintains Atmos Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATO#NYSE">ATO</a>) with a Neutral and raises the price target from $146 to $159.

UBS Maintains Neutral on Atmos Energy, Raises Price Target to $159

Timken shares are trading lower after the company narrowed FY25 EPS and sales guidance.

Baird analyst Tristan Gerra maintains Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) with a Outperform and raises the price target from $120 to $188.

Baird Maintains Outperform on Seagate Tech Hldgs, Raises Price Target to $188

BLKB

Blackbaud shares are trading higher after the company reported better-than-expected Q2 EPS and sales and raised FY25 EPS and sales guidance above estimates.

LFUS

Littelfuse shares are trading higher after the company reported better-than-expected Q2 EPS and sales.

REZI

Resideo shares are trading higher after the company announced its intention to separate its ADI business.

SLGN

Silgan Holdings shares are trading lower after the company lowered FY25 EPS guidance below estimates.

Federal Signal shares are trading higher after the company reported better-than-expected Q2 EPS and sales and raised FY25 EPS guidance.

UBS analyst Manav Gupta downgrades Chart Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>) from Buy to Neutral and lowers the price target from $225 to $210.

Downgrades

GTLS

UBS Downgrades Chart Industries to Neutral, Lowers Price Target to $210

RBC Capital analyst Sabahat Khan maintains Polaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>) with a Sector Perform and raises the price target from $34 to $56.

RBC Capital Maintains Sector Perform on Polaris, Raises Price Target to $56

Baird analyst Colin Sebastian maintains Electronic Arts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) with a Outperform and raises the price target from $168 to $170.

Baird Maintains Outperform on Electronic Arts, Raises Price Target to $170

HSBC Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSBC#NYSE">HSBC</a>) reported quarterly earnings of $1.95 per share. This is a 14.71 percent increase over earnings of $1.70 per share from the same period last year. The company reported quarterly sales of $16.473 billion which missed the analyst consensus estimate of $16.916 billion by 2.62 percent. This is a 0.41 percent decrease over sales of $16.540 billion the same period last year.

Earnings

Earnings Misses

HSBC

HSBC Holdings Q2 2025 Earnings Per ADS. EPS $1.95 Up From $1.70 YoY, Sales $16.473B Miss $16.916B Estimate

Global

Reuters Reports U.S. Oil Producer Chevron Receives Restricted U.S. Authorization To Operate In Venezuela, Sources Say

RBC Capital analyst Shagun Singh maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Outperform and lowers the price target from $330 to $325.

RBC Capital Maintains Outperform on Penumbra, Lowers Price Target to $325

Press Releases

Perspective Therapeutics to Participate in Upcoming May Investor Conferences

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

Small Cap

Opinion

Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results

High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds

Health Care

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

ALLO

AUTL

CATX

CGON

GALT

INDP

ONCY

PRPH

TSX:ONC

VSTM

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Altimmune

Amarin Corporation plc - American Depositary Shares

Amarin Corp

Annexon

Benitec Biopharma

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Crescent Biopharma

Cellectis S.A. - American Depositary Shares

Cellectis

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Heron Therapeutics

Immutep Limited - American Depositary Shares

Immutep

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Lyell Immunopharma

Monopar Therapeutics

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

Neurogene

Ocugen

Replimune Group

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics

Vanda Pharmaceuticals Inc. - Common Stock

Comments

Perspective Therapeutics

Perspective Therapeutics (CATX) Options

Perspective Therapeutics (AMEX:CATX) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL